Dr Michael O’Neill, director of research and development at Inflection Biosciences, Darren Cunningham, chief executive at Inflection and Prof Bryan Hennessy, senior clinical lecturer at RCSI and consultant medical oncologist. Photograph: Julien Behal

Irish drug development company Inflection Biosciences will present data on its fledgling breakthrough breast cancer therapy to the American Associatio(...)

Fitbit chief executive James Park: sees a future where doctors will  actually “prescribe” a Fitbit to patients. Photograph: Dara Mac Dónaill/The Irish Times

Look at the activity tracker on your wrist. Do you view it as a goal to beat on a daily basis? As a way of reducing your health insurance costs? Or a (...)

Fitbit co-founder and chief executive James Park: “I’m always kind of in survival mode, always being paranoid.” Photograph: Dara Mac Dónaill

It’s hard not to feel instantly unfit when you walk into the Fitbit offices in Dublin. Housed in the former Esat Digifone building on Baggot Street, (...)

Illustration of prostate cancer, with the bladder (brown), the seminal vesicles (pink), the vas deferens (purple), the symphysis pubis (right) and the rectum (left). Illustration: Getty Images

A landmark genetic study described as the “Rosetta stone” of prostate cancer has opened up a new era of hope for men with advanced forms of the diseas(...)

Survival rates for blood cancer have doubled in Ireland in the past five years. Photograph: Getty Images

When Gerry, a man in his early 40s, stopped responding to blood-cancer therapy, Prof Peter O’Gorman knew that his patient had reached the end of the l(...)

NUIG haematologist Prof Michael O’Dwyer: worked with Prof Lokesh Joshi of NUIG’s glysoscience group and Dr Siobhán Glavey on studying the complex sugars which cover all cells in the human body, and many of the proteins in the bloodstream.

Researchers at NUI Galway have identified an enzyme that plays a key role in the spread of blood cancer cells.The scientists say that the discovery af(...)